ALLMedicine™ Acute Bronchospasm Center
Research & Reviews 37 results
https://emedicine.medscape.com/article/2090395-overview
Feb 9th, 2020 - Reference Range Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet. [1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke...
https://emedicine.medscape.com/article/2090395-print
Feb 9th, 2020 - Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet.[1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke.[3] In the blood...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052683
American Journal of Physiology. Lung Cellular and Molecul... Ram-Mohan S, Bai Y et. al.
Nov 27th, 2019 - In asthma, acute bronchospasm is driven by contractile forces of airway smooth muscle (ASM). These forces can be imaged in the cultured ASM cell or assessed in the muscle strip and the tracheal/bronchial ring, but in each case, the ASM is studied ...
https://www.mdedge.com/pulmonary-health-hub/article/209478/asthma/fda-approves-benralizumab-autoinjector-eosinophilic?channel=94
Christopher Palmer
Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.
https://doi.org/10.4997/JRCPE.2019.307
The Journal of the Royal College of Physicians of Edinburgh; Morrow A, Ford TJ et. al.
Sep 9th, 2019 - Adenosine is frequently used during coronary angiography to induce hyperaemia and allow operators to perform quantitative measurements of lesion severity. Acute bronchospasm is a recognised side effect relating to the activation of 'off target' A2...
Guidelines 1 results
https://gskpro.com/en-us/products/nucala
NUCALA is indicated for the add-on maintenance treatment of patients 12 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.
Drugs 193 results see all →
Clinicaltrials.gov 243 results
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da6aca1a-19ed-44a4-abb7-696c7d58b784
Feb 22nd, 2021 - FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype [see Clinical Studies (14)]. Limitations of use: •FASENRA is not indicated for treatment of other ...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=038e6c40-9421-40ef-874b-8f4d7110a74a
Feb 21st, 2021 - Flovent DISKUS is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. Important Limitation of Use FLOVENT DISKUS is NOT indicated for the relief of acute bronchospasm. FLOVENT DISKUS is an ...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfaca6f9-3277-47b2-319d-1377917cb54c
Feb 16th, 2021 - ADVAIR HFA is indicated for the twice-daily treatment of asthma in patients aged 12 years and older. ADVAIR HFA should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) ...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b49ed7c1-123e-4b1d-fea6-0c6839fd9d6a
Feb 16th, 2021 - FLOVENT HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. Important Limitation of Use Flovent HFA is not indicated for the relief of acute bronchospasm. FLOVENT HFA is an inhaled c...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5061f419-5aa1-4c53-b65d-0b7f4c14b377
Feb 15th, 2021 - FLOVENT HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. Important Limitation of Use Flovent HFA is not indicated for the relief of acute bronchospasm. FLOVENT HFA is an inhaled c...
News 7 results
https://www.mdedge.com/pulmonary-health-hub/article/209478/asthma/fda-approves-benralizumab-autoinjector-eosinophilic?channel=94
Christopher Palmer
Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.
https://www.staging.medscape.com/viewarticle/853957
Nov 3rd, 2015 - The US Food and Drug Administration (FDA) approved mepolizumab (Nucala, GlaxoSmithKline) for use in combination with other medications for maintenance treatment of severe asthma in patients aged 12 years or older and with an eosinophilic phenotype...
https://www.medscape.com/viewarticle/853957
Nov 3rd, 2015 - The US Food and Drug Administration (FDA) approved mepolizumab (Nucala, GlaxoSmithKline) for use in combination with other medications for maintenance treatment of severe asthma in patients aged 12 years or older and with an eosinophilic phenotype...
https://www.medpagetoday.com/pulmonology/smokingcopd/47038
Aug 1st, 2014 - The FDA approved another once-daily bronchodilator, olodaterol (Striverdi Respimat), for maintenance treatment of chronic obstructive pulmonary disease (COPD). Approved indications for the long-acting beta-adrenergic agonist (LABA) drug included l...
https://www.medscape.com/viewarticle/503848_7
May 3rd, 2005 - Pulmonology Agents Manufacturer: Schering Drug Approval Classification: Original New Drug Application (Approval Date: 3/30/05) Indication: Asmanex Twisthaler (mometasone furoate) inhaler is indicated for the maintenance treatment of asthma as pro...